Previous 10 | Next 10 |
home / stock / gnmsf / gnmsf news
NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300. Genmab reports positive data from Phase 2 CASSIOPEIA study. For further details see: NantKwest COVID-19 Candidate, And Other ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...
Written by Nick Ackerman, co-produced by Stanford Chemist We last visited BlackRock Health Sciences Trust II ( BMEZ ) only a couple of months after its launch in January. Several months have passed, and this fund has been performing exceptionally well. While it has only been a few months...
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q2 earnings Read more ...
Genmab A/S (GMAB) Q2 2020 Results Conference Call August 12, 2020 12:00 PM ET Company Participants Jan van de Winkel - President & CEO Anthony Pagano - CFO Judith Klimovsky - CDO Anthony Mancini - EVP & COO Conference Call Participants Peter Verdult - Citi Wimal...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
Genmab A/S (GNMSF) Q1 2020 Earnings Conference Call May 06, 2020, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Anthony Mancini - EVP & COO Conference Call Participants Trung Huynh - Crédit Suisse ...
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q1 earnings Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
Genmab A/S (GNMSF) Q4 2019 Earnings Conference Call February 19, 2020 12:00 PM ET Company Participants Jan van de Winkel - Chief Executive Officer David Eatwell - Chief Financial Officer Anthony Pagano - American Senior Vice President, Finance & Corporate Development Confe...
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...